MENLO PARK, Calif., May 13, 2026 /PRNewswire/ — Apreo Health, a clinical-stage medical device company pioneering a tissue-sparing treatment for severe emphysema, today announced the appointment of David Amerson to its Board of Directors and a strategic investment from OSF Ventures, the corporate investment arm of OSF HealthCare. The company also announced it will present new clinical data at the American Thoracic Society (ATS) 2026 International Conference in Orlando, Florida.